Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 1

Status

Completed 4Unknown 2Terminated 2

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 3Genitourinary 1

Conditions

Prostatic Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Cyclophosphamide 741Cisplatin 688Gemcitabine 641Bevacizumab 616Carboplatin 605Paclitaxel 601Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 361Capecitabine 342Filgrastim 333Etoposide 330Dexamethasone 312Irinotecan 309pembrolizumab 282Leucovorin 274Cetuximab 268Cytarabine 242Erlotinib Hydrochloride 231Nivolumab 228Prednisone 227Trastuzumab 225Vincristine 221Bortezomib 221Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Completed × tetrathiomolybdate × Clear all
NCT00176800 2016-08-22

Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma

University of Michigan Rogel Cancer Center

Phase 2 Completed
69 enrolled 7 charts
Gastrointestinal

Esophageal Neoplasms

NCT00150995 2015-01-21

Tetrathiomolybdate in Hormone Refractory Prostate Cancer

University of Michigan Rogel Cancer Center

Phase 2 Completed
19 enrolled
Genitourinary

Prostatic Neoplasms

NCT00176774 2012-02-07

Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma

University of Michigan Rogel Cancer Center

Phase 2 Completed
24 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT00006332 2005-06-24

Treatment of Hepatocellular Carcinoma With Tetrathiomolybdate

National Center for Research Resources (NCRR)

Phase 2 Completed
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡